Shanghai DND Pharm-Technology Co., Inc.

Roflumilast

• Category :

  Pharmaceuticals and Biochemicals

• Synonyms :

  3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide;B 9302-107;BY 217;BYK 20869;Daxas;3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;N-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;

• CAS NO :

  162401-32-3

• EC NO :

• Molecular Formula :

  C₁₇H₁₄Cl₂F₂N₂O₃

• Molecular Weight :

  403.2075

• Main Specifications :

• InChI :

  InChI=1/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)

• Product description :

  Product name:Roflumilast Chemical name:3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide CAS No.:162401-32-3 Specification:99.0%HPLC Molecular Formula:C17H14Cl2F2N2O3 Molecular Weight:403.21 Appearance: white powder Usage:On March 1,2011, the FDA approved the chronic obstructive pneumonia drug Daliresp (roflumilast), the drug used daily, can reduce asthma attack frequency or mitigate serious chronic obstructive pneumonia (COPD) symptoms.Roflumilast is a new category of COPD drug, phosphodiesterase - 4 (PDE - 4) inhibitors. Can be used among patients with serious COPD cough and bronchial symptom related much sputum, does not apply to mild emphysema.

• Molecular Structure :